Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal
About this trial
This is an interventional treatment trial for Aplastic Anemia focused on measuring aplastic anemia, hematologic disorders, paroxysmal nocturnal hemoglobinuria, rare disease
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Acquired severe aplastic anemia or paroxysmal nocturnal hemoglobinuria Not a candidate for allogeneic bone marrow transplantation Must meet one of the following criteria: Severe aplastic anemia Less than 25% bone marrow cellularity and depression in two of three blood counts (reticulocytes less than 40,000/mm3 platelet count less than 20,000/mm3 and granulocytes less than 500/mm3) Life-threatening paroxysmal nocturnal hemoglobinuria Absolute neutrophil count less than 500/mm3 platelet transfusion dependent thrombotic disease No Fanconi anemia No abnormal cytogenetics --Patient Characteristics-- Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Cardiac ejection fraction at least 45% Other: Not preterminal or moribund Not pregnant
Sites / Locations
- Johns Hopkins Oncology Center